| A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross over Study of Oral Deucrictibant Soft Capsule for On Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema |
Ongoing |
Deucrictibant |
3 |
PHA022121-C306 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) |
Ongoing |
Nipocalimab |
3 |
80202135EBF3001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar) |
| A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM) |
Ongoing |
Tirzepatide |
4 |
I8F-MC-GPIY |
Al Moosa Specialized Hospital (al ahsa) |
| CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
Ongoing |
Camizestrant (AZD9833) |
3 |
8535C00001 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment |
Ongoing |
amlitelimab |
3 |
EFC17599 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study |
Ongoing |
Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine |
2 |
RJ19/119/J |
King Abdullah Medical Complex (Jeddah) |
| A Randomized Controlled Trial Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses |
Ongoing |
Insulin |
3 |
2023-45 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency |
Ongoing |
INZ701 |
3 |
INZ701-106 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Long-term pain and adherence observational study for Endometriosis treatment |
Ongoing |
Duphaston |
4 |
DYDR-522-0318 |
Dr.Arab Clinic |
| Real world Assessment of Dyslipidemia patients on Inclisiran effiCacy And toLerability: The RADICAL Study |
Ongoing |
LEQVIO |
4 |
CKJX839A1S |
Dallah Hospital (Riyadh) |
